No Data
Mizuho Starts Neumora at Outperform, Bullish on Lead Drug's Prospects
Mizuho Securities Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $20
Mizuho Securities analyst Graig Suvannavejh initiates coverage on $Neumora Therapeutics(NMRA.US)$ with a buy rating, and sets the target price at $20.According to TipRanks data, the analyst has a succ
Neumora Therapeutics Price Target Announced at $20.00/Share by Mizuho
Neumora Therapeutics Price Target Announced at $20.00/Share by Mizuho
Neumora Therapeutics Initiated at Outperform by Mizuho
Neumora Therapeutics Initiated at Outperform by Mizuho
Neumora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 95.12% Mizuho → $20 Initiates Coverage On → Outperform 03/28/2024 202.44% RBC Capital → $31 Rei
Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target
Neumora Therapeutics (NMRA) has average rating of buy and price targets ranging from $18 to $29, according to analysts polled by Capital IQ.